Press release
Liver Cancer Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Liver Cancer Overview
Cancer that starts in your liver's cells is called liver cancer. Your liver, an organ about the size of a football, is located in the upper right part of your abdomen, above your stomach and below your diaphragm.
"Liver Cancer Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Liver Cancer Market.
The Liver Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Liver Cancer Pipeline Report: https://www.delveinsight.com/report-store/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Liver Cancer treatment therapies with a considerable amount of success over the years. Liver Cancer Key players such as - Imvax Inc, Celldex Therapeutics, peptide RayzeBio, Siranomics, MiNA Therapeutics, Ocuphire Pharma, Medivir, Boehringer Ingelheim, Adaptimmune, TriSalus Life Sciences, Eureka Therapeutics, Medivir AB, BeiGene, Abbisko Therapeutics, Surface Oncology, Innovent Biologics, Akeso Biopharma, and others, are developing therapies for the Liver Cancer treatment
• Liver Cancer Emerging therapies such as - IHC-001, CDX-527, Research programme, STP 705, MTL-CEBPA, APX3330, Fostroxacitabine bralpamide, BI 765063, ADP-A2AFP, SD 101, ET140203, Fostrox, Ociperlimab , MTL-CEBPA, ABSK-011, SRF388, IBI310, AK104, SRF388, and others are expected to have a significant impact on the Liver Cancer market in the coming years.
• In September 2022, Akeso Biopharma initiated a randomized, double-blind, Phase III clinical study on the efficacy and safety of AK104 versus placebo as adjuvant therapy for hepatocellular carcinoma with high risk of recurrence after curative resection.
• In April 2022, Surface Oncology initiated a Phase II trial designed to evaluate the efficacy and safety ofSRF388 in combination with atezolizumab plus bevacizumab (Arm A) compared to placebo in combination with atezolizumab plus bevacizumab (Arm B) in patients with first-line advanced or metastatic HCC
Route of Administration
Liver Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Immunotherapy
Liver Cancer Pipeline Therapeutics Assessment
• Liver Cancer Assessment by Product Type
• Liver Cancer By Stage and Product Type
• Liver Cancer Assessment by Route of Administration
• Liver Cancer By Stage and Route of Administration
• Liver Cancer Assessment by Molecule Type
• Liver Cancer by Stage and Molecule Type
DelveInsight's Liver Cancer Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Some of the key companies in the Liver Cancer Therapeutics Market include:
Key companies developing therapies for the Liver Cancer treatment are - lnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Q BioMed Inc. and others.
Emerging Liver Cancer Drugs Under Different Phases of Clinical Development Include:
• IHC-001 Imvax Inc
• CDX-527: Celldex Therapeutics
• Research programme: peptide RayzeBio
• STP 705 Siranomics
• MTL-CEBPA: MiNA Therapeutics
• APX3330: Ocuphire Pharma
• Fostroxacitabine bralpamide: Medivir
• BI 765063 Boehringer Ingelheim
• ADP-A2AFP Adaptimmune
• SD 101 TriSalus Life Sciences
• ET140203 Eureka Therapeutics
• Fostrox Medivir AB
• Ociperlimab BeiGene
• MTL-CEBPA MiNA Therapeutics
• ABSK-011 Abbisko Therapeutics
• SRF388 Surface Oncology
• IBI310 Innovent Biologics
• AK104 Akeso Biopharma
• SRF388: Surface Oncology
Get a Free Sample PDF Report to know more about Liver Cancer Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Liver Cancer Pipeline Analysis:
The Liver Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Liver Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Cancer Treatment.
• Liver Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Liver Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liver Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Liver Cancer product details are provided in the report. Download the Liver Cancer pipeline report to learn more about the emerging Liver Cancer therapies at:
https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Liver Cancer Pipeline Market Drivers
• Increasing prevalence of Liver Cancer
• Increasing research and development activities
• Launch of novel drugs
Liver Cancer Pipeline Market Barriers
• Stringent regulations
• Adverse effects associated with the drugs
Scope of Liver Cancer Pipeline Drug Insight
• Coverage: Global
• Key Liver Cancer Companies: Imvax Inc, Celldex Therapeutics, peptide RayzeBio, Siranomics, MiNA Therapeutics, Ocuphire Pharma, Medivir, Boehringer Ingelheim, Adaptimmune, TriSalus Life Sciences, Eureka Therapeutics, Medivir AB, BeiGene, Abbisko Therapeutics, Surface Oncology, Innovent Biologics, Akeso Biopharma, and others
• Key Liver Cancer Therapies: IHC-001, CDX-527, Research programme, STP 705, MTL-CEBPA, APX3330, Fostroxacitabine bralpamide, BI 765063, ADP-A2AFP, SD 101, ET140203, Fostrox, Ociperlimab , MTL-CEBPA, ABSK-011, SRF388, IBI310, AK104, SRF388, and others
• Liver Cancer Therapeutic Assessment: Liver Cancer current marketed and Liver Cancer emerging therapies
• Liver Cancer Market Dynamics: Liver Cancer market drivers and Liver Cancer market barriers
Request for Sample PDF Report for Liver Cancer Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Liver Cancer Report Introduction
2 Liver Cancer Executive Summary
3 Liver Cancer Overview
4 Liver Cancer- Analytical Perspective In-depth Commercial Assessment
5 Liver Cancer Pipeline Therapeutics
6 Liver Cancer Late Stage Products (Phase II/III)
7 Liver Cancer Mid Stage Products (Phase II)
8 Liver Cancer Early Stage Products (Phase I)
9 Liver Cancer Preclinical Stage Products
10 Liver Cancer Therapeutics Assessment
11 Liver Cancer Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Liver Cancer Key Companies
14 Liver Cancer Key Products
15 Liver Cancer Unmet Needs
16 Liver Cancer Market Drivers and Barriers
17 Liver Cancer Future Perspectives and Conclusion
18 Liver Cancer Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Liver Cancer drugs and therapies- https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Liver Cancer Market https://www.delveinsight.com/report-store/liver-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Liver Cancer-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Liver Cancer Epidemiology https://www.delveinsight.com/report-store/liver-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Liver Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Related Reports By DelveInsight -
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liver Cancer Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2938828 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
